Cartesian Therapeutics, Inc. (RNAC) Stock Score, Valuation & Financial Research
Cartesian Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.
Quick answer for RNAC
Cartesian Therapeutics, Inc. currently has a Wall Street Score of 22/100. The stored market price is $8.43. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Cartesian Therapeutics, Inc. does
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC financial snapshot
- Wall Street Score:
- 22/100
- Current price:
- $8.43
- Market capitalization:
- $247.7M
- Revenue:
- $1.8M
- Net income:
- $-151.8M
- Free cash flow:
- $-79.4M
- Cash:
- $118.6M
- Total debt:
- $11.9M
- EPS:
- -5.02
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.4%.
- Free cash flow is $-79.4M, showing cash burn in the current stored period.
- The balance sheet shows $118.6M of cash versus $11.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research RNAC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.